Disease · MONDO_0004976
Comparisons in its trials87
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 20 of 87
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Dexpramipexole vs Placebo: deaths from any cause | 97 of 474 | 108 of 468 | 942 | NCT01281189 | Trial comparisons |
| Dexpramipexole vs Placebo: serious adverse events | 225 of 474 | 233 of 468 | 942 | NCT01281189 | Trial comparisons |
| Ceftriaxone vs Placebo: serious adverse events | 276 of 340 | 125 of 173 | 513 | NCT00349622 | Trial comparisons |
| Olesoxime vs Placebo Comparator: deaths from any cause | 79 of 259 | 80 of 253 | 512 | NCT00868166 | Trial comparisons |
| Olesoxime vs Placebo Comparator: serious adverse events | 68 of 259 | 65 of 253 | 512 | NCT00868166 | Trial comparisons |
| Levosimendan vs Placebo for Levosimendan: deaths from any cause | 27 of 326 | 17 of 166 | 492 | NCT03505021 | Trial comparisons |
| Levosimendan vs Placebo for Levosimendan: serious adverse events | 89 of 326 | 45 of 166 | 492 | NCT03505021 | Trial comparisons |
| Edaravone 105 mg (Once Daily) vs Edaravone 105mg (2 Weeks On/Off ): deaths from any cause | 9 of 192 | 16 of 192 | 384 | NCT04569084 | Trial comparisons |
| Edaravone 105 mg (Once Daily) vs Edaravone 105mg (2 Weeks On/Off ): serious adverse events | 52 of 192 | 55 of 191 | 383 | NCT04569084 | Trial comparisons |
| Glatiramer Acetate 40mg vs Placebo: deaths from any cause | 22 of 184 | 17 of 182 | 366 | NCT00326625 | Trial comparisons |
| Glatiramer Acetate 40mg vs Placebo: serious adverse events | 55 of 184 | 54 of 182 | 366 | NCT00326625 | Trial comparisons |
| Lithium Carbonate vs Historical Controls: deaths from any cause | 14 of 109 | 44 of 249 | 358 | NCT00790582 | Trial comparisons |
| Lithium Carbonate vs Historical Controls: serious adverse events | 62 of 109 | 91 of 249 | 358 | NCT00790582 | Trial comparisons |
| Utreloxastat vs Placebo: Number of Participants With Treatment-emergent Adverse Events (TEAEs) | 174 of 220 | 90 of 114 | 334 | NCT05349721 | Trial comparisons |
| IGF-1 vs Placebo: Number of Participants Alive and Tracheostomy-free at 24 Months | 93 of 167 | 90 of 163 | 330 | NCT00035815 | Trial comparisons |
| IGF-1 vs Placebo: serious adverse events | 18 of 167 | 12 of 163 | 330 | NCT00035815 | Trial comparisons |
| DNL343 vs Matching Placebo: Number of Participants Who Experience Death | 6 of 186 | 4 of 139 | 325 | NCT05842941 | Trial comparisons |
| DNL343 vs Matching Placebo: Number of Participants With Death or Permanent Assisted Ventilation (PAV) | 8 of 186 | 5 of 139 | 325 | NCT05842941 | Trial comparisons |
| SLS-005 vs Matching Placebo: Number of Participants That Experienced Death or Death Equivalent | 10 of 120 | 10 of 203 | 323 | NCT05136885 | Trial comparisons |
| Ozanezumab IV vs Placebo: deaths from any cause | 18 of 152 | 13 of 151 | 303 | NCT01753076 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0004976/comparisons